symbol,statement_type,period_end,line_item,value
AMBUJACEM.NS,income,2025-03-31 00:00:00,Tax Effect Of Unusual Items,-27695367.226296
AMBUJACEM.NS,income,2025-03-31 00:00:00,Tax Rate For Calcs,0.128996
AMBUJACEM.NS,income,2025-03-31 00:00:00,Normalized EBITDA,86381200000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Total Unusual Items,-214700000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Total Unusual Items Excluding Goodwill,-214700000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,41674300000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Reconciled Depreciation,24783400000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Reconciled Cost Of Revenue,65274200000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,EBITDA,86166500000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,EBIT,61383100000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Net Interest Income,-2159400000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Interest Expense,2159400000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Interest Income,
AMBUJACEM.NS,income,2025-03-31 00:00:00,Normalized Income,41861304632.773705
AMBUJACEM.NS,income,2025-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,41674300000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Total Expenses,302053900000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Rent Expense Supplemental,
AMBUJACEM.NS,income,2025-03-31 00:00:00,Diluted Average Shares,2457211085.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Basic Average Shares,2451429412.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Diluted EPS,16.96
AMBUJACEM.NS,income,2025-03-31 00:00:00,Basic EPS,17.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Diluted NI Availto Com Stockholders,41674300000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Net Income Common Stockholders,41674300000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Net Income,41674300000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Minority Interests,-9909800000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Net Income Including Noncontrolling Interests,51584100000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Net Income Continuous Operations,51584100000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Tax Provision,7639600000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Pretax Income,59223700000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Other Non Operating Income Expenses,26542500000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Special Income Charges,-214700000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Other Special Charges,-1858100000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Write Off,2072800000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Restructuring And Mergern Acquisition,0.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Net Non Operating Interest Income Expense,-2159400000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Total Other Finance Cost,
AMBUJACEM.NS,income,2025-03-31 00:00:00,Interest Expense Non Operating,2159400000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Interest Income Non Operating,
AMBUJACEM.NS,income,2025-03-31 00:00:00,Operating Income,34923100000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Operating Expense,236779700000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Other Operating Expenses,128420900000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Depreciation And Amortization In Income Statement,24783400000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Amortization,
AMBUJACEM.NS,income,2025-03-31 00:00:00,Depreciation Income Statement,24783400000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Selling General And Administration,83011900000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Selling And Marketing Expense,83011900000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,General And Administrative Expense,
AMBUJACEM.NS,income,2025-03-31 00:00:00,Rent And Landing Fees,
AMBUJACEM.NS,income,2025-03-31 00:00:00,Gross Profit,271702800000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Cost Of Revenue,65274200000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Total Revenue,336977000000.0
AMBUJACEM.NS,income,2025-03-31 00:00:00,Operating Revenue,336977000000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Tax Effect Of Unusual Items,416770760.163498
AMBUJACEM.NS,income,2024-03-31 00:00:00,Tax Rate For Calcs,0.19699
AMBUJACEM.NS,income,2024-03-31 00:00:00,Normalized EBITDA,75888100000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Total Unusual Items,2115700000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Total Unusual Items Excluding Goodwill,2115700000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,35734000000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Reconciled Depreciation,16279000000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Reconciled Cost Of Revenue,55258600000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,EBITDA,78003800000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,EBIT,61724800000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Net Interest Income,-2763800000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Interest Expense,2763800000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Interest Income,9731700000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Normalized Income,34035070760.163498
AMBUJACEM.NS,income,2024-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,35734000000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Total Expenses,280363200000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Rent Expense Supplemental,1180000000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Diluted Average Shares,2146186186.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Basic Average Shares,1987430478.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Diluted EPS,16.65
AMBUJACEM.NS,income,2024-03-31 00:00:00,Basic EPS,17.98
AMBUJACEM.NS,income,2024-03-31 00:00:00,Diluted NI Availto Com Stockholders,35734000000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Net Income Common Stockholders,35734000000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Net Income,35734000000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Minority Interests,-11612300000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Net Income Including Noncontrolling Interests,47346300000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Net Income Continuous Operations,47346300000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Tax Provision,11614700000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Pretax Income,58961000000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Other Non Operating Income Expenses,11664000000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Special Income Charges,2115700000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Other Special Charges,137200000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Write Off,0.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Restructuring And Mergern Acquisition,-2252900000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Net Non Operating Interest Income Expense,-2763800000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Total Other Finance Cost,
AMBUJACEM.NS,income,2024-03-31 00:00:00,Interest Expense Non Operating,2763800000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Interest Income Non Operating,9731700000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Operating Income,47716100000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Operating Expense,225104600000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Other Operating Expenses,118808400000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Depreciation And Amortization In Income Statement,16279000000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Amortization,582100000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Depreciation Income Statement,16279000000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Selling General And Administration,80006400000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Selling And Marketing Expense,80006400000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,General And Administrative Expense,773200000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Rent And Landing Fees,1180000000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Gross Profit,272820700000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Cost Of Revenue,55258600000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Total Revenue,328079300000.0
AMBUJACEM.NS,income,2024-03-31 00:00:00,Operating Revenue,328079300000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Tax Effect Of Unusual Items,-258233250.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Tax Rate For Calcs,0.2825
AMBUJACEM.NS,income,2021-12-31 00:00:00,Normalized EBITDA,65541000000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Total Unusual Items,-914100000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Total Unusual Items Excluding Goodwill,-914100000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,27803800000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Reconciled Depreciation,11524900000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Reconciled Cost Of Revenue,50810800000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,EBITDA,64626900000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,EBIT,53101300000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Net Interest Income,1879600000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Interest Expense,1456600000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Interest Income,3336200000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Normalized Income,28459666750.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Net Income From Continuing And Discontinued Operation,27803800000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Total Expenses,234912300000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Rent Expense Supplemental,1695800000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Diluted Average Shares,1985960632.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Basic Average Shares,1985645229.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Diluted EPS,14.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Basic EPS,14.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Diluted NI Availto Com Stockholders,27803800000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Net Income Common Stockholders,27803800000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Net Income,27803800000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Minority Interests,-9306600000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Net Income Including Noncontrolling Interests,37110400000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Net Income Continuous Operations,37110400000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Tax Provision,14534300000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Pretax Income,51644700000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Other Non Operating Income Expenses,6500000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Special Income Charges,-1095800000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Other Special Charges,1204500000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Write Off,-108700000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Restructuring And Mergern Acquisition,1204500000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Net Non Operating Interest Income Expense,1879600000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Total Other Finance Cost,70000000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Interest Expense Non Operating,1456600000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Interest Income Non Operating,3336200000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Operating Income,50568500000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Operating Expense,184101500000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Other Operating Expenses,85717800000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Depreciation And Amortization In Income Statement,11525600000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Amortization,165000000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Depreciation Income Statement,11360600000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Selling General And Administration,73859300000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Selling And Marketing Expense,73085200000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,General And Administrative Expense,774100000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Rent And Landing Fees,1695800000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Gross Profit,234670000000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Cost Of Revenue,50810800000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Total Revenue,285480800000.0
AMBUJACEM.NS,income,2021-12-31 00:00:00,Operating Revenue,285480800000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Tax Effect Of Unusual Items,-385637000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Tax Rate For Calcs,0.2225
AMBUJACEM.NS,income,2020-12-31 00:00:00,Normalized EBITDA,54669100000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Total Unusual Items,-1733200000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Total Unusual Items Excluding Goodwill,-1733200000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,23654400000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Reconciled Depreciation,11617800000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Reconciled Cost Of Revenue,47554100000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,EBITDA,52935900000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,EBIT,41318100000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Net Interest Income,2671100000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Interest Expense,1402200000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Interest Income,4073300000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Normalized Income,25001963000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Net Income From Continuing And Discontinued Operation,23654400000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Total Expenses,202010500000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Rent Expense Supplemental,1366200000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Diluted Average Shares,1985960632.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Basic Average Shares,1985645229.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Diluted EPS,11.91
AMBUJACEM.NS,income,2020-12-31 00:00:00,Basic EPS,11.91
AMBUJACEM.NS,income,2020-12-31 00:00:00,Diluted NI Availto Com Stockholders,23654400000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Net Income Common Stockholders,23654400000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Net Income,23654400000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Minority Interests,-7414000000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Net Income Including Noncontrolling Interests,31068400000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Net Income Continuous Operations,31068400000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Tax Provision,8847500000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Pretax Income,39915900000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Other Non Operating Income Expenses,22300000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Special Income Charges,-2004400000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Other Special Charges,1631000000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Write Off,373400000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Restructuring And Mergern Acquisition,
AMBUJACEM.NS,income,2020-12-31 00:00:00,Net Non Operating Interest Income Expense,2671100000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Total Other Finance Cost,60300000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Interest Expense Non Operating,1402200000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Interest Income Non Operating,4073300000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Operating Income,38928100000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Operating Expense,154456400000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Other Operating Expenses,65735600000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Depreciation And Amortization In Income Statement,11617800000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Amortization,94000000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Depreciation Income Statement,11523800000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Selling General And Administration,64437300000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Selling And Marketing Expense,63920500000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,General And Administrative Expense,516800000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Rent And Landing Fees,1366200000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Gross Profit,193384500000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Cost Of Revenue,47554100000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Total Revenue,240938600000.0
AMBUJACEM.NS,income,2020-12-31 00:00:00,Operating Revenue,240938600000.0
